These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 1832427)

  • 1. Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins.
    Pier GB; Grout M; Desjardins D
    J Immunol; 1991 Sep; 147(6):1869-76. PubMed ID: 1832427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients.
    Meluleni GJ; Grout M; Evans DJ; Pier GB
    J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Pier GB
    Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonspecific immunoglobulin synthesis and elevated IgG levels in rabbits immunized with mucoid exopolysaccharide from cystic fibrosis isolates of Pseudomonas aeruginosa.
    Pier GB; Elcock ME
    J Immunol; 1984 Aug; 133(2):734-9. PubMed ID: 6234359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
    Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R
    J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of opsonic antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide by an anti-idiotypic monoclonal antibody.
    Schreiber JR; Pier GB; Grout M; Nixon K; Patawaran M
    J Infect Dis; 1991 Sep; 164(3):507-14. PubMed ID: 1831226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.
    Theilacker C; Coleman FT; Mueschenborn S; Llosa N; Grout M; Pier GB
    Infect Immun; 2003 Jul; 71(7):3875-84. PubMed ID: 12819072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis.
    Pier GB; Saunders JM; Ames P; Edwards MS; Auerbach H; Goldfarb J; Speert DP; Hurwitch S
    N Engl J Med; 1987 Sep; 317(13):793-8. PubMed ID: 2957591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.
    Pier GB; DesJardin D; Grout M; Garner C; Bennett SE; Pekoe G; Fuller SA; Thornton MO; Harkonen WS; Miller HC
    Infect Immun; 1994 Sep; 62(9):3972-9. PubMed ID: 8063415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate).
    Hatano K; Goldberg JB; Pier GB
    Infect Immun; 1995 Jan; 63(1):21-6. PubMed ID: 7528730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody to Pseudomonas aeruginosa.
    Pier GB; Takeda S; Grout M; Markham RB
    J Clin Invest; 1993 Mar; 91(3):1079-87. PubMed ID: 8450038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection.
    Tosi MF; Zakem-Cloud H; Demko CA; Schreiber JR; Stern RC; Konstan MW; Berger M
    J Infect Dis; 1995 Aug; 172(2):453-61. PubMed ID: 7622889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide.
    Garner CV; DesJardins D; Pier GB
    Infect Immun; 1990 Jun; 58(6):1835-42. PubMed ID: 2140341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance.
    Zaragoza O; Casadevall A
    Cell Microbiol; 2006 Dec; 8(12):1862-76. PubMed ID: 16824038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum bactericidal activity and phagocytosis in host defence against Haemophilus ducreyi.
    Lagergård T; Frisk A; Purvèn M; Nilsson LA
    Microb Pathog; 1995 Jan; 18(1):37-51. PubMed ID: 7783597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opsonization of mucoid and non-mucoid Pseudomonas aeruginosa by serum from patients with cystic fibrosis assessed by a chemiluminescence assay.
    LeBlanc CM; Bortolussi R; Issekutz AC; Gillespie T
    Clin Invest Med; 1982; 5(2-3):125-8. PubMed ID: 6811181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic variability of X-protein expression by mastitis-causing Streptococcus agalactiae of serotype NT/X and opsonic activities of specific antibodies.
    Rainard P; Sarradin P; Poutrel B
    Microb Pathog; 1994 May; 16(5):359-72. PubMed ID: 7815919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies directed against gonococcal protein I vary in bactericidal activity.
    Joiner KA; Warren KA; Tam M; Frank MM
    J Immunol; 1985 May; 134(5):3411-9. PubMed ID: 3920319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance of Actinobacillus pleuropneumoniae to bactericidal antibody and complement is mediated by capsular polysaccharide and blocking antibody specific for lipopolysaccharide.
    Ward CK; Inzana TJ
    J Immunol; 1994 Sep; 153(5):2110-21. PubMed ID: 8051416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.